GUARNERI, Valentina
GUARNERI, Valentina
Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer
2017 Conte, P; Bisagni, G; Frassoldati, A; Brandes, A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Musolino, A; Garrone, O; Donadio, M; Cavazzini, G; Turletti, A; Zamagni, C; Danese, S; Ferro, A; Piacentini, F; Balduzzi, S; D'Amico, R; Guarneri, V
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS
2010 Barbieri, E.; Bettelli, S.; Piacentini, F.; Ficarra, G.; Conte, Pf.; Guarneri, V.
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio
2018 Conte, P. F.; Guarneri, V.; Bisagni, G.; Piacentini, F.; Brandes, A. A.; Cavanna, L.; Giotta, F.; Aieta, M.; Gebbia, V.; Frassoldati, A.; Musolino, A.; Garrone, O.; Taverniti, C.; Rimanti, A.; Sarti, S.; Rubino, D.; Bologna, A.; Vicini, R.; Balduzzi, S.; D'Amico, R.
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study.
2018 Conte, P; Frassoldati, A; Bisagni, G; Brandes, Aa; Donadio, M; Garrone, O; Piacentini, F; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Molino, A; Musolino, A; Ferro, A; Maltoni, R; Danese, S; Zamagni, C; Rimanti, A; Cagossi, K; Russo, A; Pronzato, P; Giovanardi, F; Moretti, G; Lombardo, L; Schirone, A; Beano, A; Amaducci, L; Bajardi, Ea; Vicini, R; Balduzzi, Sara; D'Amico, R; Guarneri, Valentina
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER.
2010 Guarneri, Valentina; Frassoldati, A; Gebbia, V; Bisagni, G; Cavanna, L; Donadio, M; Lelli, G; Musolino, A; Colucci, G; Banna, Gl; Degli Esposti, R; Ferro, A; Grasso, F; Zamagni, C; Amadori, D; Aieta, M; Molino, A; Garrone, O; Aitini, E; Fornari, G; Cascinu, Stefano; Rossi, G; D'Amico, Roberto; Conte, Pierfranco
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
2020 Prat, A; Guarneri, V; Paré, L; Griguolo, G; Pascual, T; Dieci, Mv; Chic, N; González-Farré, B; Frassoldati, A; Sanfeliu, E; Cejalvo, Jm; Muñoz, M; Bisagni, G; Brasó-Maristany, F; Urso, L; Vidal, M; Brandes, Aa; Adamo, B; Musolino, A; Miglietta, F; Conte, B; Oliveira, M; Saura, C; Pernas, S; Alarcón, J; Llombart-Cussac, A; Cortés, J; Manso, L; López, R; Ciruelos, E; Schettini, F; Villagrasa, P; Carey, La; Perou, Cm; Piacentini, F; D'Amico, R; Tagliafico, E; Parker, Js; Conte, P
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)
2023 Cortesi, L.; Venturelli, M.; Cortesi, G.; Caggia, F.; Toss, A.; Barbieri, E.; De Giorgi, U.; Guarneri, V.; Musolino, A.; De Matteis, E.; Zambelli, A.; Bisagni, G.; Dominici, M.
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy
2008 Guarneri, Valentina; Piacentini, Federico; A., Frassoldati; G., Ficarra; D'Amico, Roberto; Giovannelli, Simona; Conte, Pierfranco
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy.
2009 Guarneri, Valentina; Piacentini, Federico; Ficarra, G; Frassoldati, A; D'Amico, Roberto; Giovannelli, Simona; Maiorana, Antonino; Jovic, Gordana; Conte, Pierfranco
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer
2023 Miglietta, Federica; Ragazzi, Moira; Fernandes, Bethania; Griguolo, Gaia; Massa, Davide; Girardi, Fabio; Bottosso, Michele; Bisagni, Alessandra; Zarrilli, Giovanni; Porra, Francesca; Iannaccone, Daniela; Dore, Leocadia; Gaudio, Mariangela; Santandrea, Giacomo; Fassan, Matteo; Lo Mele, Marcello; De Sanctis, Rita; Zambelli, Alberto; Bisagni, Giancarlo; Guarneri, Valentina; Dieci, Maria Vittoria
Achievements and unmet needs in the management of advanced ovarian cancer
2010 Guarneri, Valentina; Piacentini, Federico; Barbieri, Elena; Conte, Pierfranco
ACHIEVEMENTS AND UNMET NEEDS IN THE MANAGEMENT OF EPITHELIAL OVARIAN CANCER
2010 Conte, P.; Piacentini, F.; Barbieri, E.; Guarneri, V.
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy
2004 A., Gennari; P., Bruzzi; C., Orlandini; B., Salvadori; S., Donati; E., Landucci; Guarneri, Valentina; M., Rondini; S., Ricci; Conte, Pierfranco
Acute and subacute toxicities of medical anticancer treatment. ESMO handbook of cancer diagnosis and treatment evaluation, pag 79-99 . Informa Healthcare USA, 2009, ISBN 978-1-841-84703-0
2009 Guarneri, Valentina; Conte, Pierfranco
Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study
2021 Dieci, M. V.; Carbognin, L.; Cumerlato, E.; Canino, F.; Griguolo, G.; Giorgi, C. A.; Amato, O.; Genovesi, E.; Garufi, G.; Giannarelli, D.; Tornincasa, A.; Trudu, L.; Michieletto, S.; Saibene, T.; Conte, P.; Piacentini, F.; Bria, E.; Guarneri, V.
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials
2009 Guarneri, Valentina; Miles, D; Robert, Nj; Dieras, Vc; Glaspy, J; Smith, Ie; Thomssen, C; Biganzoli, L; Taran, T; Conte, Pierfranco
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial.
2009 Guarneri, Valentina; A., Frassoldati; A., Bottini; K., Cagossi; L., Cavanna; A., Ravaioli; D., Amadori; G., Giardina; C., Oliva; Conte, Pierfranco
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
2010 Guarneri, Valentina; Barbieri, Elena; Dieci, Mv; Piacentini, Federico; Conte, Pierfranco
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
2019 Dieci, Mv; Conte, P; Bisagni, G; Brandes, Aa; Frassoldati, A; Cavanna, L; Musolino, A; Giotta, F; Rimanti, A; Garrone, O; Bertone, E; Cagossi, K; Sarti, S; Ferro, A; Piacentini, F; Maiorana, A; Orvieto, E; Sanders, M; Miglietta, F; Balduzzi, S; D'Amico, R; Guarneri, V.
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
2010 Guarneri, Valentina; Miles, D; Robert, N; Diéras, V; Glaspy, J; Smith, I; Thomssen, C; BiganzoliL, ; Taran, T; Conte, Pierfranco
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer | 1-gen-2017 | Conte, P; Bisagni, G; Frassoldati, A; Brandes, A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Musolino, A; Garrone, O; Donadio, M; Cavazzini, G; Turletti, A; Zamagni, C; Danese, S; Ferro, A; Piacentini, F; Balduzzi, S; D'Amico, R; Guarneri, V | |
| 35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS | 1-gen-2010 | Barbieri, E.; Bettelli, S.; Piacentini, F.; Ficarra, G.; Conte, Pf.; Guarneri, V. | |
| 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio | 1-gen-2018 | Conte, P. F.; Guarneri, V.; Bisagni, G.; Piacentini, F.; Brandes, A. A.; Cavanna, L.; Giotta, F.; Aieta, M.; Gebbia, V.; Frassoldati, A.; Musolino, A.; Garrone, O.; Taverniti, C.; Rimanti, A.; Sarti, S.; Rubino, D.; Bologna, A.; Vicini, R.; Balduzzi, S.; D'Amico, R. | |
| 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. | 1-gen-2018 | Conte, P; Frassoldati, A; Bisagni, G; Brandes, Aa; Donadio, M; Garrone, O; Piacentini, F; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Molino, A; Musolino, A; Ferro, A; Maltoni, R; Danese, S; Zamagni, C; Rimanti, A; Cagossi, K; Russo, A; Pronzato, P; Giovanardi, F; Moretti, G; Lombardo, L; Schirone, A; Beano, A; Amaducci, L; Bajardi, Ea; Vicini, R; Balduzzi, Sara; D'Amico, R; Guarneri, Valentina | |
| 9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. | 1-gen-2010 | Guarneri, Valentina; Frassoldati, A; Gebbia, V; Bisagni, G; Cavanna, L; Donadio, M; Lelli, G; Musolino, A; Colucci, G; Banna, Gl; Degli Esposti, R; Ferro, A; Grasso, F; Zamagni, C; Amadori, D; Aieta, M; Molino, A; Garrone, O; Aitini, E; Fornari, G; Cascinu, Stefano; Rossi, G; D'Amico, Roberto; Conte, Pierfranco | |
| A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation | 1-gen-2020 | Prat, A; Guarneri, V; Paré, L; Griguolo, G; Pascual, T; Dieci, Mv; Chic, N; González-Farré, B; Frassoldati, A; Sanfeliu, E; Cejalvo, Jm; Muñoz, M; Bisagni, G; Brasó-Maristany, F; Urso, L; Vidal, M; Brandes, Aa; Adamo, B; Musolino, A; Miglietta, F; Conte, B; Oliveira, M; Saura, C; Pernas, S; Alarcón, J; Llombart-Cussac, A; Cortés, J; Manso, L; López, R; Ciruelos, E; Schettini, F; Villagrasa, P; Carey, La; Perou, Cm; Piacentini, F; D'Amico, R; Tagliafico, E; Parker, Js; Conte, P | |
| A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA) | 1-gen-2023 | Cortesi, L.; Venturelli, M.; Cortesi, G.; Caggia, F.; Toss, A.; Barbieri, E.; De Giorgi, U.; Guarneri, V.; Musolino, A.; De Matteis, E.; Zambelli, A.; Bisagni, G.; Dominici, M. | |
| A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy | 1-gen-2008 | Guarneri, Valentina; Piacentini, Federico; A., Frassoldati; G., Ficarra; D'Amico, Roberto; Giovannelli, Simona; Conte, Pierfranco | |
| A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. | 1-gen-2009 | Guarneri, Valentina; Piacentini, Federico; Ficarra, G; Frassoldati, A; D'Amico, Roberto; Giovannelli, Simona; Maiorana, Antonino; Jovic, Gordana; Conte, Pierfranco | |
| A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer | 1-gen-2023 | Miglietta, Federica; Ragazzi, Moira; Fernandes, Bethania; Griguolo, Gaia; Massa, Davide; Girardi, Fabio; Bottosso, Michele; Bisagni, Alessandra; Zarrilli, Giovanni; Porra, Francesca; Iannaccone, Daniela; Dore, Leocadia; Gaudio, Mariangela; Santandrea, Giacomo; Fassan, Matteo; Lo Mele, Marcello; De Sanctis, Rita; Zambelli, Alberto; Bisagni, Giancarlo; Guarneri, Valentina; Dieci, Maria Vittoria | |
| Achievements and unmet needs in the management of advanced ovarian cancer | 1-gen-2010 | Guarneri, Valentina; Piacentini, Federico; Barbieri, Elena; Conte, Pierfranco | |
| ACHIEVEMENTS AND UNMET NEEDS IN THE MANAGEMENT OF EPITHELIAL OVARIAN CANCER | 1-gen-2010 | Conte, P.; Piacentini, F.; Barbieri, E.; Guarneri, V. | |
| Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy | 1-gen-2004 | A., Gennari; P., Bruzzi; C., Orlandini; B., Salvadori; S., Donati; E., Landucci; Guarneri, Valentina; M., Rondini; S., Ricci; Conte, Pierfranco | |
| Acute and subacute toxicities of medical anticancer treatment. ESMO handbook of cancer diagnosis and treatment evaluation, pag 79-99 . Informa Healthcare USA, 2009, ISBN 978-1-841-84703-0 | 1-gen-2009 | Guarneri, Valentina; Conte, Pierfranco | |
| Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study | 1-gen-2021 | Dieci, M. V.; Carbognin, L.; Cumerlato, E.; Canino, F.; Griguolo, G.; Giorgi, C. A.; Amato, O.; Genovesi, E.; Garufi, G.; Giannarelli, D.; Tornincasa, A.; Trudu, L.; Michieletto, S.; Saibene, T.; Conte, P.; Piacentini, F.; Bria, E.; Guarneri, V. | |
| Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials | 1-gen-2009 | Guarneri, Valentina; Miles, D; Robert, Nj; Dieras, Vc; Glaspy, J; Smith, Ie; Thomssen, C; Biganzoli, L; Taran, T; Conte, Pierfranco | |
| Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. | 1-gen-2009 | Guarneri, Valentina; A., Frassoldati; A., Bottini; K., Cagossi; L., Cavanna; A., Ravaioli; D., Amadori; G., Giardina; C., Oliva; Conte, Pierfranco | |
| Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer | 1-gen-2010 | Guarneri, Valentina; Barbieri, Elena; Dieci, Mv; Piacentini, Federico; Conte, Pierfranco | |
| Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. | 1-gen-2019 | Dieci, Mv; Conte, P; Bisagni, G; Brandes, Aa; Frassoldati, A; Cavanna, L; Musolino, A; Giotta, F; Rimanti, A; Garrone, O; Bertone, E; Cagossi, K; Sarti, S; Ferro, A; Piacentini, F; Maiorana, A; Orvieto, E; Sanders, M; Miglietta, F; Balduzzi, S; D'Amico, R; Guarneri, V. | |
| Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. | 1-gen-2010 | Guarneri, Valentina; Miles, D; Robert, N; Diéras, V; Glaspy, J; Smith, I; Thomssen, C; BiganzoliL, ; Taran, T; Conte, Pierfranco |